TRCT
PHAS

Tower Research Capital (TRC)’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Tower Research Capital (TRC)’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,603
Closed -$2K – 6874
2022
Q3 		$2K Sell
10,603
-14,600
-58% -$14.9K ﹤0.01% 5714
2022
Q2 		$15K Buy
25,203
+24,950
+9,862% +$23.9K ﹤0.01% 4117
2022
Q1 		$0 Buy
253
+143
+130% +$232 ﹤0.01% 7029
2021
Q4 		$0 Sell
110
-8,012
-99% -$24.2K ﹤0.01% 6917
2021
Q3 		$26K Buy
8,122
+4,557
+128% +$15.2K ﹤0.01% 3504
2021
Q2 		$13K Sell
3,565
-131
-4% -$436 ﹤0.01% 4258
2021
Q1 		$13K Sell
3,696
-6,190
-63% -$25.1K ﹤0.01% 4233
2020
Q4 		$33K Sell
9,886
-6,779
-41% -$24.3K ﹤0.01% 3502
2020
Q3 		$58K Buy
16,665
+13,605
+445% +$54.8K ﹤0.01% 3479
2020
Q2 		$14K Buy
3,060
+2,236
+271% +$9.9K ﹤0.01% 3885
2020
Q1 		$3K Buy
824
+451
+121% +$2.06K ﹤0.01% 2517
2019
Q4 		$2K Sell
373
-1,329
-78% -$5.47K ﹤0.01% 3156
2019
Q3 		$7K Buy
1,702
+1,276
+300% +$10.2K ﹤0.01% 3174
2019
Q2 		$6K Buy
+426
New +$5.22K ﹤0.01% 2893
2019
Q1 		– Sell
-408
Closed -$1K – 4492
2018
Q4 		$1K Buy
+408
New +$1.62K ﹤0.01% 3704

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Tower Research Capital (TRC)'s PHAS Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 10,603 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in PHAS in Q4 2018 and held it in 15 quarters. The position peaked at $58K in Q3 2020. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Tower Research Capital (TRC) reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 10,603 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $2K.
  • Tower Research Capital (TRC) first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 15 quarters.
  • Tower Research Capital (TRC)'s PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $58K in Q3 2020.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.